These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 20729301)

  • 1. Change in serum lipids after acute coronary syndromes: secondary analysis of SPACE ROCKET study data and a comparative literature review.
    Barth JH; Jackson BM; Farrin AJ; Efthymiou M; Worthy G; Copeland J; Bailey KM; Romaine SP; Balmforth AJ; McCormack T; Whitehead A; Flather MD; Nixon J; Hall AS;
    Clin Chem; 2010 Oct; 56(10):1592-8. PubMed ID: 20729301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, controlled trial of simvastatin versus rosuvastatin in patients with acute myocardial infarction: the Secondary Prevention of Acute Coronary Events--Reduction of Cholesterol to Key European Targets Trial.
    Hall AS; Jackson BM; Farrin AJ; Efthymiou M; Barth JH; Copeland J; Bailey KM; Romaine SP; Balmforth AJ; McCormack T; Whitehead A; Flather MD; Nixon J;
    Eur J Cardiovasc Prev Rehabil; 2009 Dec; 16(6):712-21. PubMed ID: 19745745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: the GEOSTAT-1 Study.
    Bailey KM; Romaine SP; Jackson BM; Farrin AJ; Efthymiou M; Barth JH; Copeland J; McCormack T; Whitehead A; Flather MD; Samani NJ; Nixon J; Hall AS; Balmforth AJ;
    Circ Cardiovasc Genet; 2010 Jun; 3(3):276-85. PubMed ID: 20207952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of rosuvastatin on serum lipids and arteriosclerosis in dyslipidemic patients with cerebral infarction.
    Deguchi I; Horiuchi Y; Hayashi T; Sehara Y; Kato Y; Ohe Y; Fukuoka T; Maruyama H; Sano H; Nagamine Y; Tanahashi N
    J Stroke Cerebrovasc Dis; 2014 Sep; 23(8):2007-2011. PubMed ID: 25066602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals.
    Shepherd J; Hunninghake DB; Barter P; McKenney JM; Hutchinson HG
    Am J Cardiol; 2003 Mar; 91(5A):11C-17C; discussion 17C-19C. PubMed ID: 12646338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid levels after acute coronary syndromes.
    Pitt B; Loscalzo J; Ycas J; Raichlen JS
    J Am Coll Cardiol; 2008 Apr; 51(15):1440-5. PubMed ID: 18402897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effects of different statins, ezetimibe/simvastatin combination on hsCRP levels in unstable angina pectoris and non-ST elevation myocardial infarction patients: a randomized trial].
    Namal E; Sener N; Ulaş T; Akçalı Z; Oztekin E; Borlu F
    Anadolu Kardiyol Derg; 2011 Dec; 11(8):703-10. PubMed ID: 22088858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE; Feely J; Sigurdsson EL;
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rosuvastatin prevents myocardial necrosis in an experimental model of acute myocardial infarction.
    Dourado PM; Tsutsui JM; Landim MB; Casella Filho A; Galvao TF; Aiello VD; Mathias W; da Luz PL; Chagas AC
    Braz J Med Biol Res; 2011 May; 44(5):469-76. PubMed ID: 21445530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin.
    Rader DJ; Davidson MH; Caplan RJ; Pears JS
    Am J Cardiol; 2003 Mar; 91(5A):20C-23C; discussion 23C-24C. PubMed ID: 12646340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial.
    McKenney JM; Jones PH; Adamczyk MA; Cain VA; Bryzinski BS; Blasetto JW;
    Curr Med Res Opin; 2003; 19(8):689-98. PubMed ID: 14687438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daily and intermittent rosuvastatin 5 mg therapy in statin intolerant patients: an observational study.
    Meek C; Wierzbicki AS; Jewkes C; Twomey PJ; Crook MA; Jones A; Viljoen A
    Curr Med Res Opin; 2012 Mar; 28(3):371-8. PubMed ID: 22256801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).
    Jones PH; Davidson MH; Stein EA; Bays HE; McKenney JM; Miller E; Cain VA; Blasetto JW;
    Am J Cardiol; 2003 Jul; 92(2):152-60. PubMed ID: 12860216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Non-ST-elevation acute coronary syndrome. Comparison of effects of atorvastatin and rosuvastatin on blood levels of lipids and markers of inflammation].
    Kuznetsova MA; Vaulin NA; Masenko VP; Gratsianskiĭ NA
    Kardiologiia; 2010; 50(2):21-5. PubMed ID: 20146674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Negative effects of termination statinotherapy in patients after acute coronary event with concominent non-alcoholic steatohepatitis].
    Skrypnyk IM; Dubrovins'ka TV
    Lik Sprava; 2014 Nov; (11):106-11. PubMed ID: 25528845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disappointing recent cholesterol-lowering drug trials: is it not time for a full reappraisal of the cholesterol theory?
    de Lorgeril M
    World Rev Nutr Diet; 2009; 100():80-89. PubMed ID: 19696530
    [No Abstract]   [Full Text] [Related]  

  • 17. Impact of intensive lipid lowering on lipid profiles over time and tolerability in stable coronary artery disease: insights from a subanalysis of the coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS).
    Kawashiri MA; Yamagishi M; Sakamoto T; Takayama T; Hiro T; Daida H; Hirayama A; Saito S; Yamaguchi T; Matsuzaki M;
    Cardiovasc Ther; 2013 Dec; 31(6):335-43. PubMed ID: 23409830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial.
    Ridker PM; Genest J; Boekholdt SM; Libby P; Gotto AM; Nordestgaard BG; Mora S; MacFadyen JG; Glynn RJ; Kastelein JJ;
    Lancet; 2010 Jul; 376(9738):333-9. PubMed ID: 20655105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.
    Stender S; Schuster H; Barter P; Watkins C; Kallend D;
    Diabetes Obes Metab; 2005 Jul; 7(4):430-8. PubMed ID: 15955130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of atorvastatin on interventional therapy in patients with acute myocardial infarction.
    Wang K; Chen L; Liu L; Cui Y; Zhang X; Jiang J
    Minerva Med; 2019 Apr; 110(2):101-106. PubMed ID: 29696937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.